The estimated Net Worth of Dror Bashan is at least 737 千$ dollars as of 19 October 2023. Mr Bashan owns over 64,516 units of Protalix BioTherapeutics stock worth over 137,817$ and over the last 5 years he sold PLX stock worth over 0$. In addition, he makes 599,387$ as Pres、 CEO & Director at Protalix BioTherapeutics.
Mr has made over 2 trades of the Protalix BioTherapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 64,516 units of PLX stock worth 90,322$ on 19 October 2023.
The largest trade he's ever made was buying 68,000 units of Protalix BioTherapeutics stock on 11 April 2022 worth over 102,000$. On average, Mr trades about 16,565 units every 70 days since 2019. As of 19 October 2023 he still owns at least 132,516 units of Protalix BioTherapeutics stock.
You can see the complete history of Mr Bashan stock trades at the bottom of the page.
Dror Bashan is the Pres, CEO & Director at Protalix BioTherapeutics.
As the Pres、 CEO & Director of Protalix BioTherapeutics, the total compensation of Mr Bashan at Protalix BioTherapeutics is 599,387$. There are 1 executives at Protalix BioTherapeutics getting paid more, with Dr. Einat Brill-Almon having the highest compensation of 665,703$.
Mr Bashan is 54, he's been the Pres、 CEO & Director of Protalix BioTherapeutics since . There are 10 older and 3 younger executives at Protalix BioTherapeutics. The oldest executive at Protalix BioTherapeutics Inc. is Aharon Schwartz, 75, who is the Independent Director.
Dror's mailing address filed with the SEC is C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, L3, 2161401.
Over the last 18 years, insiders at Protalix BioTherapeutics have traded over 46,705,936$ worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth 4,673,005$ . The most active insiders traders include Phillip Md Et Al Frost Gamm...、Capital Management Lp Camber、Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of 404,231$. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth 90,322$.
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase
Protalix BioTherapeutics executives and other stock owners filed with the SEC include: